Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands
Suzanne I.M. Neppelenbroek , Yvonne M. Geurts , Berthe M.P. Aleman , Cecile P.M. Janus , Saskia E Rademakers , Roel J. de Weijer , Richard W.M. Van Der Maazen , Josée M. Zijlstra , Max Beijert , Karijn M.S. Verschueren , Bastiaan Ta , Marten R. Nijziel , Eduardus F.M. Posthuma , Marie José Kersten , Karin Muller , Liane te Boome , Yavuz Bilgin , Eva de Jongh , Michael Schaapveld , Flora Van Leeuwen
Background: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Recently concern has been raised that anthracyclines may also increase BC risk, based on studies in childhood cancer survivors with/without a history of chest RT. So far, the association between anthracyclines and BC risk has not been examined in cancer survivors treated at adolescent/adult ages. Now that RT dose and volumes are decreasing, the potential contribution of anthracyclines to BC risk is an important issue. Methods: We assessed BC risk in a cohort of 2314 female 5-year HL survivors, treated at ages 15-50 years and diagnosed between 1965 and 2008 in 20 Dutch hospitals. Treatment factors were time-dependently included in the analysis, focusing on the effect of anthracycline exposure on BC risk. Results: After a median follow-up of 18.8 years, 258 women developed invasive BC or ductal carcinoma in situ as a subsequent malignancy. The 30-year cumulative incidence was 15.0% (95% Confidence Interval (CI) 12.8-17.4%). Mantle field RT (or other RT involving both axillae) was associated with increased risk of BC (Hazard ratio (HR) 1.9; 95% CI 1.2-2.8) compared to no supradiaphragmatic RT or RT to the neck only (Table 1). Gonadotoxic treatment (>4.2 g/m2 procarbazine or pelvic RT) significantly decreased this risk. In a multivariable analysis, anthracycline exposure was associated with increased BC risk (HR 1.8; 95% CI 1.3-2.5) in patients who received a cumulative dose of >200 mg/m2. Among patients exposed to gonadotoxic treatment, the HR of BC associated with >200mg/m2 anthracyclines was 3.8 (95% CI 2.0-7.2), with a trend for higher risk with higher anthracycline dose (HR 1.58 per 100mg/m2 anthracycline, p<0.001). Conclusions: Our results suggest an association of anthracyclines with BC risk in HL survivors. Also when accounting for the protective effect of gonadotoxic treatment on RT-associated BC risk, anthracyclines significantly contributed to a higher BC risk.
Cox PH regression model of anthracycline exposure and breast cancer risk. | ||||
---|---|---|---|---|
Number of patients N=2314 | Events (%) N=258 | Hazard ratio (95% CI) | ||
Anthracyclines | ||||
No anthracyclines | 994 | 172 (17.3%) | 1.0 | |
35-200 mg/m2 (median: 150 mg/m2) | 471 | 21 (4.5%) | 1.5 (0.9-2.5) | |
>200 mg/m2 (median: 245 mg/m2) | 793 | 64 (8.1%) | 1.8 (1.3-2.5) | |
Unknown | 56 | 1 (1.8%) | 0.3 (0.0-2.0) | |
Supradiaphragmatic RT | ||||
No supradiaphragmatic RT | 356 | 20 (5.6%) | 1.0 | |
Incomplete mantle field | 968 | 48 (5.0%) | 0.9 (0.5-1.5) | |
Full mantle field | 990 | 190 (19.2%) | 1.9 (1.2-3.1) | |
Gonadotoxic therapy | ||||
No procarbazine or pelvic RT | 1213 | 160 (13.2%) | 1.0 | |
No pelvic RT &<=4.2 g/m2 procarbazine | 453 | 43 (9.5%) | 0.8 (0.5-1.2) | |
No pelvic RT &>4.2 and <8.4 g/m2 procarbazine | 331 | 35 (10.6%) | 0.7 (0.4-1.0) | |
No pelvic RT &>=8.4 g/m2 procarbazine | 124 | 9 (7.3%) | 0.4 (0.2-0.9) | |
Pelvic RT | 193 | 11 (5.7%) | 0.3 (0.1-0.6) |
RT: radiotherapy; adjusted for age at first treatment.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Georgina Virginia Whelan
2021 ASCO Annual Meeting
First Author: Florence Lennie Wong
2024 ASCO Annual Meeting
First Author: Jennifer M Yeh
2024 ASCO Annual Meeting
First Author: Lauren Victoria Ghazal